Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07492134 · ClinicalTrials.gov registry record · Phase 2
APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT07492134 is a Phase 2 study that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 100 participants.
The verdict
NCT07492134, a Phase 2 study, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to determine whether antibiotics improve recovery from acute uncomplicated diverticulitis (AUD) in racially and ethnically diverse United States clinical practice. The main questions it seeks to answer are: * What is the feasibility for completing a subsequent definitive efficacy trial of antibiotics vs. placebo to treat AUD? * What are the needs for successful recruitment of racial and ethnic subgroups? * What are the effects of a placebo compared to antibiotics for AUD on a range of key patient-centric efficacy and safety endpoints? * How do such effects differ by race and ethnicity? Researchers will compare a placebo to antibiotics to see if AUD can be treated without using antibiotics. Participants will: * Take two antibiotics or a matching placebo every day for 10 days * Receive analgesia, gastric protection, diet modifications, and a follow-up * Submit daily photos of pills to the study team to verify adherence
Interventions
- DRUG Placebo
- DRUG Metronidazole
- DRUG Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
- DRUG Cefuroxime
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07-07 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07492134
The ClinicalTrials.gov registry entry for NCT07492134 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07492134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07492134 about?
NCT07492134 is a clinical study titled "APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)". The goal of this clinical trial is to determine whether antibiotics improve recovery from acute uncomplicated diverticulitis (AUD) in racially and ethnically diverse United States clinical practice. The main questions it seeks to answer are: * What is the feasibility for completing a subsequent def...
What is the current status of trial NCT07492134?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-07-07. Estimated completion is 2028-10-01.
What interventions are being tested in trial NCT07492134?
The interventions under investigation include: Placebo (DRUG), Metronidazole (DRUG), Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet (DRUG), Cefuroxime (DRUG).
Who is sponsoring clinical trial NCT07492134?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.